|
|
 |
|
The Leadership Behind Trimeris
Martin A. Mattingly, Chief Executive Officer and member of the Company's board of directors. Dr. Mattingly was most recently employed at Ambrx, Inc. where he served as President and Chief Executive Officer from 2005 to 2007. Prior to that, Dr. Mattingly served as Executive Vice President and Chief Operating Officer at CancerVax from 2003 to 2005. From 1996 to 2003, he provided senior leadership in various management positions at Agouron Pharmaceuticals, Inc. ("Agouron") and Pfizer, Inc. ("Pfizer"). These assignments included General Manager of the Agouron HIV division; Vice President, Product Development Group at Pfizer; and Vice President, Global Marketing Planning at Pfizer. From 1983 to 1996, Dr. Mattingly held various positions in oncology marketing and sales management at Eli Lilly and Company.
Dr. Mattingly holds a Doctor of Pharmacy degree from the University of Kentucky.
Andrew L. Graham, CPA, Corporate Secretary and Chief Financial Officer. Mr. Graham joined Trimeris in September 2004. Prior to joining Trimeris, Mr. Graham served as Chief Accounting Officer at Icoria, Inc. (formerly Paradigm Genetics, Inc.) from 2002 through 2004. At Icoria, Mr. Graham first served as Comptroller and later as Director of Finance from 1999 through 2002. Mr. Graham received his BA and MA degrees in accounting from North Carolina State University, and his MBA from the University of North Carolina at Chapel Hill.
Michael A. Alrutz, General Counsel. Dr. Alrutz previously served as Legal Counsel at Trimeris beginning in 2002. Dr. Alrutz received his B.A. degree in Biology from the University of Pennsylvania and his J.D. from Duke University School of Law. Dr. Alrutz also holds a Ph.D. in Molecular Biology from the Sackler School of Graduate Biomedical Sciences at Tufts University.
Trimeris Board of Directors
Felix J. Baker, Ph.D. has served as a director of Trimeris since April 2004. Dr. Baker is a
Managing Member of Baker Bros. Advisors, LLC, which he and his brother, Julian
Baker, founded in 2000. Dr. Baker’s firm manages Baker Brothers Investments, a
family of long-term investment funds for major university endowments and
foundations, which are focused on publicly-traded life sciences companies.
Dr. Baker’s career as a fund manager began in 1994 when he co-founded a
biotechnology investing partnership with the Tisch family. He is also a director
of Ardea Bioscience, Inc., and Seattle Genetics, Inc.
Dr. Baker was previously a director of Conjuchem Inc. until February 2010 and Neurogen Corporation until December 2009.
Dr. Baker holds a B.S. and a Ph.D. in Immunology from Stanford University, where
he also completed two years of medical school. We believe Dr. Baker’s
qualifications to serve on the Board of Directors include his experiences in the
fields of finance and biotechnology. The doctor is a highly experienced
director, having served on the board of directors of numerous public and private
biopharmaceutical corporations. In addition, Dr. Baker has extensive technical
expertise relevant to our business in the areas of immunology, infectious
disease and molecular biology.
Julian C. Baker has served as a director of Trimeris since April 2004. Mr. Baker is a
Managing Member of Baker Bros. Advisors, LLC, which he and his brother, Felix
Baker, Ph.D., founded in 2000. Mr. Baker’s firm manages Baker Brothers
Investments, a family of long-term investment funds for university endowments
and foundations, which are focused on publicly-traded life sciences companies.
Mr. Baker’s career as a fund manager began in 1994 when he co-founded a
biotechnology investing partnership with the Tisch family. Previously, Mr. Baker
was employed from 1988 to 1993 by the private equity investment arm of Credit
Suisse First Boston Corporation. He was also a director of Incyte Corporation,
and Genomic Health, Inc. In addition, Mr. Baker was previously a director of
Neurogen Corporation until December 2009. Mr. Baker holds an A.B. magna cum laude
from Harvard University. We believe
Mr. Baker’s qualifications to serve on the Board of Directors include his
experience in the field of finance and his extensive knowledge of the
biopharmaceutical industry. Mr. Baker is a highly experienced director, having
served on the board of directors of numerous public and private
biopharmaceutical corporations.
Stephen R. Davis has been a director since June 2007. Mr. Davis is the
former President and Chief Executive Officer of Neurogen Corporation following
its acquisition by Ligand Pharmaceuticals in December 2009. Prior to being named
CEO in February 2008, Mr. Davis served as Chief Operating Officer of Neurogen
beginning in April 2005 and Vice President from September 2001 through April
2005. Mr. Davis was also a director of Neurogen. Mr. Davis joined Neurogen in
1994 as Vice President of Finance and Chief Financial Officer. From 1990 through
June 1994, Mr. Davis was employed by Milbank, Tweed, Hadley & McCloy LLP as a
corporate and securities attorney. Previously, Mr. Davis practiced as a
Certified Public Accountant with Arthur Andersen & Co. Mr. Davis received his
B.S. in Accounting from Southern Nazarene University and a J.D. from Vanderbilt
University. We believe Mr. Davis’ qualifications to serve on the Board of
Directors include his experience in the field of finance and extensive
experience having held numerous senior positions at biopharmaceutical
corporations.
Martin A. Mattingly, Pharm.D. has been our President
and Chief Executive Officer
since November 14, 2007, and was appointed to the Board of Directors on
November 14, 2007. Dr. Mattingly was most recently employed at Ambrx, Inc.,
where he served as President and Chief Executive Officer from September 2005 to
2007. Prior to Ambrx, Dr. Mattingly served as Executive Vice President and Chief
Operating Officer at CancerVax, Inc. from May 2003 to September 2005. From 1996
to 2003, Dr. Mattingly provided senior leadership in various management
positions at Agouron Pharmaceuticals, Inc. and Pfizer, Inc. These assignments
included General Manager of the Agouron HIV division; Vice President, Product
Development Group at Pfizer; and Vice President, Global Marketing Planning at
Pfizer. From 1983 to 1996, Dr. Mattingly held various positions in oncology
marketing and sales management at Eli Lilly and Company. We believe
Dr. Mattingly’s qualifications to serve on the Board of Directors include his
three decades in the biotechnology and pharmaceuticals industries, including two
years as our Chief Executive Officer.
Barry Quart, Pharm.D. has been a director of Trimeris since June 2007. Since late 2006,
Dr. Quart has served as President and CEO of Ardea Biosciences, Inc., a
publicly-traded biotechnology firm. From 2002 until December 2006, Dr. Quart was
President of Napo Pharmaceuticals, Inc. Prior to his leadership of Napo,
Dr. Quart was Senior Vice President, Pfizer Global Research and Development and
the Director of Pfizer’s La Jolla Laboratories. Prior to Pfizer’s acquisition of
the Warner-Lambert Company, Dr. Quart was President of Research and Development
at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company,
since 1999. Prior to joining Agouron in 1993, Dr. Quart spent over ten years at
Bristol-Myers Squibb in both Clinical Research and Regulatory Affairs. Dr. Quart
has a Pharm.D. from the University of California, San Francisco. We believe
Dr. Quart’s qualifications to serve on the Board of Directors include his three
decades in the biotechnology and pharmaceuticals industries, particularly with
respect to HIV therapeutics.
James R. Thomas has been a director of the Company since August 2009. From 1990 to 2009,
Mr. Thomas served in various financial positions at Pfizer, Inc. From 2007 to
2009, Mr. Thomas served as CFO of Pfizer’s Specialty Markets and Special
Entities division. In addition, from 2003 to 2007, Mr. Thomas served as CFO of
Greenstone, LLC (Pfizer Generics) and from 2001-2003 Mr. Thomas served as the
CFO for Agouron Pharmaceuticals, Inc. Mr. Thomas holds B.S. and M.B.A. degrees
from Indiana State University School of Business. We believe Mr. Thomas’
qualifications to serve on the Board of Directors includes his experience in the
field of finance, manufacturing of pharmaceutical and iopharmaceutical products
and pharmaceutical commercial strategy.
|
|
|
|
 |
| Science can provide an answer, but the medicine provides new hope. |
|
 |
|
|
|